# Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

> **NCT02564523** · PHASE2 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 1075 (actual)

## Conditions studied

- Hemorrhagic Fever, Ebola

## Interventions

- **BIOLOGICAL:** Ad26.ZEBOV
- **BIOLOGICAL:** MVA-BN-Filo
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02564523
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-06
- **Primary completion:** 2019-02-12
- **Final completion:** 2019-02-12
- **Target enrollment:** 1075 (ACTUAL)
- **Last updated:** 2022-03-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02564523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02564523, "Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02564523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*